Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo

Lignende værker

• The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment
  af: van den Heuvel, Lambertus P., et al.
  Udgivet: (2020)
• Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria
  af: Eliesen, Gaby A.M., et al.
  Udgivet: (2020)
• Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
  af: Wijnsma, Kioa Lente, et al.
  Udgivet: (2019)
• Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person
  af: Bergseth, Grethe, et al.
  Udgivet: (2011)
• Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report
  af: Gustavsen, Alice, et al.
  Udgivet: (2017)